Home > Pulmonology > ERS 2019 > COPD Management > Dual Bronchodilation Improves Ventilation Dynamics in COPD Patients

Dual Bronchodilation Improves Ventilation Dynamics in COPD Patients

Conference
ERS 2019
Trial
Cohort study, CLAIM

Novel results from the CLAIM study demonstrate better pulmonary ventilation/perfusion match and ventilation dynamics when hyperinflated chronic obstructive pulmonary disease (COPD) patients are treated with indacaterol/glycopyrronium.

Dual bronchodilation in combination with a long-acting β agonist and a muscarinic receptor antagonist was found to decline hyperinflation and increase heart function in the CLAIM trial [1]. The study included 62 COPD patients with hyperinflation expressed by a residual volume of >135% at baseline. All patients were ≥40 years old and had smoked for ≥10 pack-years. The new investigation analysed treatment effects on pulmonary ventilation/perfusion match (VQM) and regional ventilation dynamics by comparing indacaterol/glycopyrronium versus placebo in the CLAIM cohort [2].

Participants were randomised 1:1. Group 1 first received indacaterol/glycopyrronium at a dosage of 110/50 μg per day for 14 days followed by another ...



please login to read the entire article:


You need to register to read the entire article, please do so now.





Posted on